

20 June 2018

To: Recipients of POCT13, 3rd ed.
From: Jennifer K. Adams, MT(ASCP), MSHA
Vice President, Standards and Quality
Subject: Correction

This notification is to inform you of corrections made to CLSI document POCT13, *Glucose Monitoring in Settings Without Laboratory Support*, 3rd ed. Recently, CLSI was informed of a potential patient safety issue related to this guideline. The issue cited and corrections made are described below.

Issue

POCT13 does not provide sufficient clarity regarding the use of lancing devices and glucose meters. This ambiguity could lead to unsafe practices that may put patients at risk of infection. Unsafe practices during assisted monitoring of blood glucose and insulin administration have contributed to hepatitis B virus transmission and/or put patients at risk for infection. Examples of unsafe practices include:

- Using fingerstick devices for more than one person, even when the lancet is changed
- Using a blood glucose meter for more than one person without cleaning and disinfecting it between uses
- Failing to change gloves and perform hand hygiene between fingerstick procedures
- Using insulin pens for more than one person

Corrections

Corrections made to the guideline are intended to clarify that:

- Single-use, autodisable lancing devices should be used in settings where assisted monitoring of blood glucose is performed.
- Only those glucose meters specifically designated by the manufacturer as appropriate for multipatient use are to be used on more than one person.
- Manufacturer's instructions for cleaning and disinfection between patients for multipatient use glucose meters must be followed.

Corrections were made in the following chapters and subchapters:

- In Subchapter 1.4.2, the definition of lancing device was expanded for clarification.
- In Chapter 2, recommendations regarding the use of lancing devices, lancets, and glucose meters to prevent transmission of bloodborne pathogens were strengthened. Recommendations regarding the use of devices for dispensing insulin were added.
- In Chapter 3, the glucose monitoring program coordinator's responsibilities for infection control were clarified, including training and oversight practices.
- In Chapter 4, the intended use of blood glucose meters (ie, individual vs multipatient use meters) was clarified.
- In Chapter 5, the safety recommendations to prevent the transmission of bloodborne pathogens were improved.

If you previously purchased POCT13, an electronic version of the corrected guideline will be e-mailed to you. If you do not receive the e-mail or experience any issues with the corrected file, or if you require any additional clarification regarding these corrections, please contact CLSI Customer Service at customerservice@clsi.org or +1.610.688.0100.

We appreciate your commitment to CLSI and regret any inconvenience.